Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ofloxacin + metronidazole is a fixed-dose combination medication containing two active pharmaceutical ingredients: ofloxacin (a fluoroquinolone antibiotic) and metronidazole (a nitroimidazole-class antiprotozoal and antibacterial agent). This combination is used to treat a variety of mixed bacterial and protozoal infections, particularly in the gastrointestinal tract (such as diarrhea and dysentery), genitourinary tract, respiratory system, skin/soft tissue infections, pelvic inflammatory disease, bacterial vaginosis, gynecological infections, dental abscesses/infections, intra-abdominal infections, and post-surgical infections[1][3][4][5]. - Ofloxacin acts by inhibiting bacterial DNA gyrase and topoisomerase IV enzymes involved in DNA replication—preventing cell division and leading to bactericidal activity against susceptible bacteria. - Metronidazole works by entering anaerobic bacteria/protozoa cells where it disrupts their DNA structure through reduction reactions—resulting in cell death. It is effective against anaerobic bacteria as well as protozoan parasites such as Entamoeba histolytica[1][4][5]. The combination provides broad-spectrum coverage for mixed aerobic-anaerobic or protozoal-bacterial infections. Both drugs are small molecules administered orally or via suspension formulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ofloxacin + metronidazole.